Is ARTL or ADXN more profitable?

Addex Therapeutics' return on equity of -134.76% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% Addex Therapeutics N/A -134.76% -106.00%

Does the media favor ARTL or ADXN?

In the previous week, Addex Therapeutics had 4 more articles in the media than Artelo Biosciences. MarketBeat recorded 7 mentions for Addex Therapeutics and 3 mentions for Artelo Biosciences. Addex Therapeutics' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, PCSA or ARTL?

Heatwurx is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Artelo Biosciences N/A N/A -$12.88M -$16.80 N/A

Is PCSA or ARTL more profitable?

Heatwurx's return on equity of -394.25% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Artelo Biosciences N/A -518.27% -194.29%

Do analysts prefer NCNA or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation & earnings, NCNA or ARTL?

NuCana is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Artelo Biosciences N/A N/A -$12.88M -$16.80 N/A

Is NCNA or ARTL more profitable?

NuCana's return on equity of -41.90% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Artelo Biosciences N/A -518.27% -194.29%

Do analysts recommend SNOA or ARTL?

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer SNOA or ARTL?

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 3 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Artelo Biosciences' score of -0.64 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend GELS or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, GELS or ARTL?

Gelteq has higher revenue and earnings than Artelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 55.21 -$4.30M N/A N/A Artelo Biosciences N/A N/A -$12.88M -$16.80 N/A

Is GELS or ARTL more profitable?

Gelteq's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Artelo Biosciences N/A -518.27% -194.29%

Does the media prefer GELS or ARTL?

In the previous week, Gelteq and Gelteq both had 3 articles in the media. Gelteq's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that Gelteq is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Artelo Biosciences (ARTL) Competitors

$0.72 +0.03 (+4.09%)

Closing price 04:00 PM Eastern

Extended Trading

$0.71 0.00 (-0.45%)

As of 05:14 PM Eastern

Compare

ARTL vs. ADXN, PCSA, NCNA, SNOA, and GELS

Should you buy Artelo Biosciences stock or one of its competitors? Artelo Biosciences's main competitors and comparable companies include Addex Therapeutics (ADXN), Heatwurx (PCSA), NuCana (NCNA), Sonoma Pharmaceuticals (SNOA), and Gelteq (GELS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Artelo Biosciences compare to Addex Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Artelo Biosciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Addex Therapeutics had 4 more articles in the media than Artelo Biosciences. MarketBeat recorded 7 mentions for Addex Therapeutics and 3 mentions for Artelo Biosciences. Addex Therapeutics' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics' return on equity of -134.76% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Addex Therapeutics	N/A	-134.76%	-106.00%

Artelo Biosciences currently has a consensus target price of $54.00, suggesting a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Artelo Biosciences is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Addex Therapeutics has higher revenue and earnings than Artelo Biosciences. Addex Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A
Addex Therapeutics	$210K	22.84	-$8.12M	-$5.94	N/A

Summary

Addex Therapeutics beats Artelo Biosciences on 10 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Heatwurx is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A

Heatwurx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Heatwurx currently has a consensus price target of $25.00, suggesting a potential upside of 1,046.79%. Artelo Biosciences has a consensus price target of $54.00, suggesting a potential upside of 7,429.28%. Given Artelo Biosciences' higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Artelo Biosciences had 1 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Artelo Biosciences and 2 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Neutral
Artelo Biosciences	Negative

Heatwurx's return on equity of -394.25% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Artelo Biosciences	N/A	-518.27%	-194.29%

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Heatwurx beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to NuCana?

NuCana (NASDAQ:NCNA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

NuCana is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

NuCana has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

44.0% of NuCana shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Artelo Biosciences had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Artelo Biosciences and 1 mentions for NuCana. NuCana's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Neutral
Artelo Biosciences	Negative

NuCana's return on equity of -41.90% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Artelo Biosciences	N/A	-518.27%	-194.29%

Summary

NuCana beats Artelo Biosciences on 7 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 3 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Artelo Biosciences' score of -0.64 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sonoma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Sonoma Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Artelo Biosciences has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Artelo Biosciences	N/A	-518.27%	-194.29%

Sonoma Pharmaceuticals has higher revenue and earnings than Artelo Biosciences. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A

Summary

Sonoma Pharmaceuticals beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to Gelteq?

Gelteq (NASDAQ:GELS) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Gelteq and Gelteq both had 3 articles in the media. Gelteq's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.64 indicating that Gelteq is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artelo Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Gelteq has a beta of -0.45, indicating that its share price is 145% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Gelteq has higher revenue and earnings than Artelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	55.21	-$4.30M	N/A	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A

Gelteq's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Artelo Biosciences	N/A	-518.27%	-194.29%

0.9% of Artelo Biosciences shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,429.28%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Gelteq and Artelo Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.17M	$12.54B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-0.04	778.14	270.94	24.14
Price / Sales	N/A	754.40	634.77	96.69
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.66	12.02	13.14	6.25
Net Income	-$12.88M	$2.80B	$3.46B	$347.86M
7 Day Performance	-1.74%	3.95%	3.23%	1.57%
1 Month Performance	-29.69%	6.54%	8.82%	5.24%
1 Year Performance	-97.47%	8.76%	27.70%	17.87%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	2.3407 of 5 stars	$0.72 +4.1%	$54.00 +7,429.3%	-97.5%	$3.17M	N/A	N/A	5	Short Interest Decrease
ADXN Addex Therapeutics	0.2214 of 5 stars	$5.60 -1.7%	N/A	-49.5%	$7.33M	$210K	N/A	30	Short Interest Increase
PCSA Heatwurx	2.9156 of 5 stars	$2.10 -1.4%	$25.00 +1,090.5%	-60.2%	$6.73M	N/A	N/A	20	Negative News Short Interest Decrease Gap Up
NCNA NuCana	0.9776 of 5 stars	$1.52 -1.9%	N/A	-57.3%	$6.62M	N/A	N/A	30	Positive News
SNOA Sonoma Pharmaceuticals	1.1336 of 5 stars	$1.30 -1.5%	N/A	-73.7%	$6.22M	$19.53M	N/A	180	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. ADXN, PCSA, NCNA, SNOA, and GELS

How does Artelo Biosciences compare to Addex Therapeutics?

Summary

How does Artelo Biosciences compare to Heatwurx?

Summary

How does Artelo Biosciences compare to NuCana?

Summary

How does Artelo Biosciences compare to Sonoma Pharmaceuticals?

Summary

How does Artelo Biosciences compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. ADXN, PCSA, NCNA, SNOA, and GELS

How does Artelo Biosciences compare to Addex Therapeutics?

Do insiders & institutionals hold more shares of ARTL or ADXN?

Which has more volatility and risk, ARTL or ADXN?

Does the media favor ARTL or ADXN?

Is ARTL or ADXN more profitable?

Do analysts prefer ARTL or ADXN?

Which has better earnings and valuation, ARTL or ADXN?

Summary

How does Artelo Biosciences compare to Heatwurx?

Which has better valuation & earnings, PCSA or ARTL?

Which has more risk and volatility, PCSA or ARTL?

Do analysts rate PCSA or ARTL?

Does the media favor PCSA or ARTL?

Is PCSA or ARTL more profitable?

Do insiders and institutionals hold more shares of PCSA or ARTL?

Summary

How does Artelo Biosciences compare to NuCana?

Which has better valuation & earnings, NCNA or ARTL?

Do analysts prefer NCNA or ARTL?

Which has more volatility & risk, NCNA or ARTL?

Do institutionals & insiders believe in NCNA or ARTL?

Does the media prefer NCNA or ARTL?

Is NCNA or ARTL more profitable?

Summary

How does Artelo Biosciences compare to Sonoma Pharmaceuticals?

Do insiders & institutionals believe in SNOA or ARTL?

Does the media prefer SNOA or ARTL?

Which has more volatility & risk, SNOA or ARTL?

Do analysts recommend SNOA or ARTL?

Is SNOA or ARTL more profitable?

Which has better earnings & valuation, SNOA or ARTL?

Summary

How does Artelo Biosciences compare to Gelteq?

Does the media prefer GELS or ARTL?

Which has more risk and volatility, GELS or ARTL?

Which has higher valuation & earnings, GELS or ARTL?

Is GELS or ARTL more profitable?

Do insiders and institutionals believe in GELS or ARTL?

Do analysts recommend GELS or ARTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools